CTLA4 and lung adenocarcinoma: In another two cohorts [7, 15], a total of two patients (study IDs were CR4880 and PR4092, [15]) with melanoma who received anti‐CTLA4 therapy and one patient with lung adenocarcinoma (study ID was DI6359, [7]) who received anti‐PD‐1 therapy were verified to harbor PRKDC mutations.